Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

The trade threats could reduce exports to the United States and dampen investment in Europe, dealing a blow to growth at a ...

Sudair Pharma aims to localise insulin production, contributing to the continuity of supply and reducing reliance on imports ...

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.